---
title: "Imlunestrant and Abemaciclib for the Treatment of Estrogen Receptor Positive Breast Cancer in Patients With Minimal Residual Disease, MIRI Trial"
date: "2025-09-25T04:00:00.000Z"
publishedDate: "25 septembre 2025"
summary: "Conditions : Anatomic Stage I Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8; Invasive Breast Carcinoma; Localized Estrogen Receptor-Positive Breast Carcinoma; Localized Human Epidermal Growth Factor Receptor (HER2)-Negative Breast Carcinoma Interventions : Drug: Abemaciclib; Procedure: Biospecimen Collection; Drug: Imlunestrant; Other: Questionnaire Administration; Procedure: Radiologic Imaging Procedure Sponsors : Jonsson Comprehensive Cancer Center Not yet recruiting"
importance: ""
sourceUrl: "https://clinicaltrials.gov/study/NCT07191717?term=interventional+radiology&aggFilters=status%3A"
tags: ["France", "Actualité", "ClinicalTrials.gov — ta recherche"]
permalink: "/papers/2025-09-25-imlunestrant-and-abemaciclib-for-the-treatment-of-estrogen-receptor-positive-breast-cancer-in-patients-with-minimal-residual-disease-miri-trial"
imageUrl: ""
imageCredit: ""
---

## L’essentiel

Conditions : Anatomic Stage I Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8; Invasive Breast Carcinoma; Localized Estrogen Receptor-Positive Breast Carcinoma; Localized Human Epidermal Growth Factor Receptor (HER2)-Negative Breast Carcinoma Interventions : Drug: Abemaciclib; Procedure: Biospecimen Collection; Drug: Imlunestrant; Other: Questionnaire Administration; Procedure: Radiologic Imaging Procedure Sponsors : Jonsson Comprehensive Cancer Center Not yet recruiting

## Lien source

https://clinicaltrials.gov/study/NCT07191717?term=interventional+radiology&aggFilters=status%3A
